These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26439158)

  • 1. Letter to the Editor: "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women" by Iepsen E.W., et al.
    Conte C; Cecere A; Guglielmi G; Napoli N
    J Clin Endocrinol Metab; 2015 Oct; 100(10):L92-3. PubMed ID: 26439158
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Liraglutide-Induced Increase in Bone Formation Can Be Dependent on Osteocalcin.
    Kizilgul M; Kan S; Beysel S; Delibasi T
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L71. PubMed ID: 26339737
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to the Letter by Napoli N., et al.
    Iepsen EW
    J Clin Endocrinol Metab; 2015 Oct; 100(10):L94-5. PubMed ID: 26439159
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to the Letter by Kizilgul M., et al.
    Iepsen EW
    J Clin Endocrinol Metab; 2015 Sep; 100(9):L72. PubMed ID: 26339738
    [No Abstract]   [Full Text] [Related]  

  • 5. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1R agonists are not a quick fix for weight loss.
    Iverson KA
    BMJ; 2012 Feb; 344():e1455; author reply e1459. PubMed ID: 22374905
    [No Abstract]   [Full Text] [Related]  

  • 10. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 11. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.
    Clemmensen C; Chabenne J; Finan B; Sullivan L; Fischer K; Küchler D; Sehrer L; Ograjsek T; Hofmann SM; Schriever SC; Pfluger PT; Pinkstaff J; Tschöp MH; Dimarchi R; Müller TD
    Diabetes; 2014 Apr; 63(4):1422-7. PubMed ID: 24379349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of GLP-1R agonists in diabetes requires long term study.
    de Oliveira JM
    BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
    Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E
    Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GLP-1 agonist supports weight loss].
    Weiß M
    MMW Fortschr Med; 2016 Feb; 158(2):71. PubMed ID: 26961053
    [No Abstract]   [Full Text] [Related]  

  • 16. [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].
    Marques AR; Jaafar J; de Kalbermatten B; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1227-8, 1230-3. PubMed ID: 26211282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
    Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
    Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of GLP1 receptor agonists and body mass control].
    Žák P; Olšovský J
    Vnitr Lek; 2015 Apr; 61(4):316-9. PubMed ID: 25894261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anorexigenic effects of GLP-1 and its analogues.
    Gallwitz B
    Handb Exp Pharmacol; 2012; (209):185-207. PubMed ID: 22249815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.